Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41587-020-00001-3
Updates & Corrections
-
Correction 03 June 2020: In the original version of this article, Timothy Yu’s comment that "academics are not well positioned to lead the charge for n-of-one therapies" is inaccurate. Yu thinks that academic medical centers will play a key role in developing n-of-one therapies, although they aren’t positioned to scale up yet. Also, the cost Yu mentions for oligonucleotide synthesis refers to research grade oligonucleotides, not clinical grade ones, which are more expensive. The text has been corrected to address these errors.